A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Rafael Rosell(Hospital Universitario Dexeus), Julie R. Brahmer(Johns Hopkins University), David Planchard(Université Paris-Saclay), Robert C. Doebele(Aurora University), Luís A. López(Universidad de Oviedo), Scott Gettinger(Yale Cancer Center), Christian Schumann(University Hospital Ulm), Barbara Atkins(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyun Li(Nanjing University), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 42
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k